PolyBio Research Foundation receives $15M for extended Long COVID research and clinical trials
Retrieved on:
星期三, 十一月 1, 2023
Principal, J. Craig Venter Institute, Laboratory, Cohen Center for Holocaust and Genocide Studies, Core, Harvard Medical School, Coronavirus, UCSF, Karolinska Institute, Johns Hopkins University, Assistant, SARS-CoV-2, Nature Immunology, Physician, Icahn School of Medicine at Mount Sinai, Atmosphere, Research, Virus, University of Pennsylvania, Multimedia, University of California, San Francisco, Aerosol, COVID, Vitalik Buterin, Consortium, Clinical trial, COVID-19, Mount Sinai, N95, University, HEPA, San Francisco, Alzheimer's disease, Patient, Infection, Pharmaceutical industry, Vaccine, Long COVID, Ethereum, Medicine
MEDFORD, Mass., Nov. 1, 2023 /PRNewswire/ -- PolyBio Research Foundation has announced a $15M gift from Kanro: a philanthropic fund to support scientific research established by Vitalik Buterin, co-founder of Ethereum. The funding will support a second phase of research and clinical trials via the LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly and openly study core biological drivers of Long COVID. This is Buterin's second $15M gift to the Consortium and will allow dozens of new projects to move forward.
Key Points:
- The funding will support a second phase of research and clinical trials via the LongCovid Research Consortium (LCRC): a global scientific collaboration to rapidly and openly study core biological drivers of Long COVID.
- LCRC research thus far demonstrates that reservoirs of the virus can persist for months - or even years - in the tissue of Long COVID patients.
- "Mechanisms underlying Long COVID are not a mystery," says Dr. Amy Proal PhD, PolyBio's Chief Scientific Officer.
- "The persistence of SARS-CoV-2 in tissue is a major target for rapid research and clinical trials."